Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Cancer Immunotherapy and Vaccines Research 2.0
share announcement

Cancer Immunotherapy and Vaccines Research 2.0

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 3367

Special Issue Editor

Dr. Luigi Buonaguro

E-Mail Website
Guest Editor
Innovative Immunological Models Unit, National Cancer Institute - IRCCS “Pascale”, Via Mariano, Semmola, 52, 80131 Napoli, Italy
Interests: cancer immunotherapy; cancer vaccines; hepatocellular carcinoma; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer vaccines are one of the main pillars of the cancer immunotherapy even in the era of checkpoint inhibitors. Indeed, although the latter have completely changed the scenario of cancer treatment, several patients do not benefit from them. However, the cancer vaccine field is still a work in progress field because an effective strategy has not been developed yet. The topic of the special issue will cover all the aspects involved in the vaccine research and development (i.e., identification of optimal target antigens, formulations, delivery strategies, adjuvants, combination with other immunomodulatory approaches).

Dr. Luigi Buonaguro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer vaccines
  • cancer immunotherapy
  • immunomodulatory
  • strategies
  • delivery strategies
  • adjuvants

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

29 pages, 2684 KiB  
Review
A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects
by Roberto Zefferino and Massimo Conese
Vaccines 2023, 11(11), 1701; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines11111701 - 08 Nov 2023
Cited by 1 | Viewed by 1065
Abstract
Is it possible to have an available vaccine that eradicates cancer? Starting from this question, this article tries to verify the state of the art, proposing a different approach to the issue. The variety of cancers and different and often unknown causes of [...] Read more.
Is it possible to have an available vaccine that eradicates cancer? Starting from this question, this article tries to verify the state of the art, proposing a different approach to the issue. The variety of cancers and different and often unknown causes of cancer impede, except in some cited cases, the creation of a classical vaccine directed at the causative agent. The efforts of the scientific community are oriented toward stimulating the immune systems of patients, thereby preventing immune evasion, and heightening chemotherapeutic agents effects against cancer. However, the results are not decisive, because without any warning signs, metastasis often occurs. The purpose of this paper is to elaborate on a vaccine that must be administered to a patient in order to prevent metastasis; metastasis is an event that leads to death, and thus, preventing it could transform cancer into a chronic disease. We underline the fact that the field has not been studied in depth, and that the complexity of metastatic processes should not be underestimated. Then, with the aim of identifying the target of a cancer vaccine, we draw attention to the presence of the paradoxical actions of different mechanisms, pathways, molecules, and immune and non-immune cells characteristic of the tumor microenvironment at the primary site and pre-metastatic niche in order to exclude possible vaccine candidates that have opposite effects/behaviors; after a meticulous evaluation, we propose possible targets to develop a metastasis-targeting vaccine. We conclude that a change in the current concept of a cancer vaccine is needed, and the efforts of the scientific community should be redirected toward a metastasis-targeting vaccine, with the increasing hope of eradicating cancer. Full article
(This article belongs to the Special Issue Cancer Immunotherapy and Vaccines Research 2.0)
►▼ Show Figures

Figure 1

17 pages, 310 KiB  
Review
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines
by Anna Hargrave, Abu Salim Mustafa, Asma Hanif, Javed H. Tunio and Shumaila Nida M. Hanif
Vaccines 2023, 11(11), 1633; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines11111633 - 25 Oct 2023
Cited by 3 | Viewed by 1927
Abstract
Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of [...] Read more.
Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise. This review is focused on previously United States Food and Drug Administration-approved cancer therapeutic vaccines and neoantigen-based vaccine developments along with the associated relevant clinical trials. Full article
(This article belongs to the Special Issue Cancer Immunotherapy and Vaccines Research 2.0)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop